A damning assessment of the cost-benefit of vesicular monoamine transporter-2 (VMAT2) inhibitors for management of tardive dyskinesia (TD) has been released by USA-based not-for-profit Institute for Clinical and Economic Review (ICER).
The Evidence Report assessed the comparative clinical effectiveness and value of three treatments for TD, a movement disorder often associated with long-term use of certain antipsychotic drugs.
"Current prices are far out of alignment with the benefits measured in clinical trials"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze